Compare Conagra Brands Inc (CAG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs Inovio Pharmaceuticals Inc — how do they compare? Conagra Brands Inc trades at $15.01 (market cap $7.14B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Conagra Brands Inc is far larger — about 90.9× Inovio Pharmaceuticals Inc's market cap, and Conagra Brands Inc pays a 8.2% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CAG | INO | |
|---|---|---|
Market Cap | $7.14B | $78.55M |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $2.87 |
52-Week Low | $12.58 | $0.66 |
Enterprise Value | $14.20B | $49.56M |
Dividend Yield | 8.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $14.985, up 1.39% with neutral technical signals. The company shows mixed fundamentals with a P/E of 10.06 and P/S of 0.63 suggesting undervaluation, but negative net income margin (-16.99%) and ROE (-25.06%) reflect profitability challenges. Recent earnings show two beats and one miss in the last four quarters, with Q3 2026 results pending. The company recently cut its dividend by 50% to prioritize debt reduction and operational improvements under new CEO John Brase.
CAG presents a turnaround story with attractive valuation metrics but faces significant headwinds including declining sales, margin pressure, and high debt levels. Analyst consensus is cautious with 62.5% hold ratings and a $13.67 price target below current levels. The dividend cut provides financial flexibility but signals ongoing challenges. Investors should weigh the discounted valuation against persistent operational pressures and weak growth outlook.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
